Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CHICAGO--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from the primary analysis of the Phase 3 TROPiCS-02 study of Trodelvy® (sacituzumab govitecan-hziy) versus physicians' choice of chemotherapy (TPC) in heavily pre-treated HR+/HER2- metastatic breast cancer patients who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy. The study met its primary endpoint of progression-free survival (PFS) with a statistically si

Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced findings from a safety and efficacy retrospective analysis by race and ethnicity from the ongoing post-authorization study of Yescarta® (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cell lymphoma (LBCL). In the largest real-world analysis of its kind evaluating data from the CIBMTR® (Center for International Blood and Marrow Transplant Research®), overall outcomes incl

Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity

Gilead Sciences, Inc. (NASDAQ:GILD ) Bernstein 38th Annual Strategic Decisions Conference June 1, 2022 4:30 PM ET CorporateParticipants Andrew Dickinson - Chief Financial Officer ConferenceCall Participants Ronny Gal - Bernstein Okay, let's go ahead and start. Let's get the last tech people scurry out of the room, we don't need them.

Gilead Sciences, Inc. (GILD) Management presents at Bernstein 38th Annual Strategic Decisions Conference - Transcript

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Stacey Ma, PhD will join the company as Executive Vice President, Pharmaceutical Development and Manufacturing, and will become a member of the company's senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O'Day. Dr. Ma will assume responsibility for Gilead's Pharmaceutical Development and Manufacturing organization effective July 18, 2022. Dr. Ma will succeed Dr. Yang, w

Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing

AstraZeneca

Roche Holding AG

Daiichi Sankyo Co Ltd

Investors will want to keep an eye on developments at this week's meeting of the American Society of Clinical Oncology in Chicago, where four members of big pharma will share study results of their most promising cancer drugs. The news has the potential to move the shares of the presenters-- Daiichi Sankyo Co. Ltd.

ASCO Presentations Could Move Shares of Daiichi, AstraZeneca, Gilead and Roche

Chevron

Dow Inc

Energy Transfer LP Unit

iShares Core High Dividend ETF

Intel

AT&T

Investors are seeking dividend stocks. Here are seven safe dividend stocks that offer a high yield to maximize their total return.

7 Safe Dividend Stocks With High Yields to Buy Now

Starbucks

Verizon

I have added to my taxable account 3.6133 shares for a total investment of $250.00 in Starbucks Corporation. I have added to my taxable account 11.5718 shares for a total investment of $550.00 in Verizon Communications.

Recent Stock Purchase May 2022

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today was officially recognized as the number one philanthropic funder of HIV-related programs in a new tracking report released by Funders Concerned About AIDS (FCAA). The report, found at: https://www.fcaaids.org/inform/philanthropic-support-to-address-hiv-aids/, is released annually and is widely regarded as the most comprehensive study of its kind. It analyzes 2020 funding data (the most recent year available) reveal

Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report

FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that more than 20 abstracts, including two oral presentations and four poster discussions, will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. These data highlight promising targets across diverse tumor types and blood cancers, including hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+

Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting

Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.

Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the company's Investigational New Drug Application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP). As previously announced, the FDA had placed a clinical hold on the use of injectable lenacapavir in borosilicate vials due to a vial compatibility issue. FDA removed the clin

FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV

Consider these issues before buying shares of the drugmaker.

2 Red Flags for Gilead Sciences' Future

Amgen

VanEck Vectors Biotech ETF

Biogen

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

How Are Biotech ETFs Reacting to These Q1 Earnings Releases?

Cytokinetics

Biotech is one of the hardest hit sectors this year, with the SPDR S&P Biotech ETF now down 45% year-to-date. Still, a Mizuho analyst says the following two stocks are worth buying.

Mizuho: these two biotech stocks are worth buying right now

Alpha and Omega Semiconductor

CF Industries Holdings

Intrepid Potash

Mosaic

Moderna

Sanderson Farms

Companies with high debt lived in a sort of paradise in 2019 to 2021. With interest rates extraordinarily low, their debt burden didn't hurt.

Now's the Time for Low-Debt Stocks to Pay Off

Gilead is still, by and large, an HIV company.

Is Gilead Sciences Too Dependent On These 2 Areas of Its Business?

Gilead Sciences has been forgotten, as the once promising growth potential has disappeared. The company has handled the LOE for its HIV assets well, and is continuing to see overall revenue increase albeit slowly.

Gilead Sciences: A Forgotten Company

Kraft Heinz

Walgreens

The Nasdaq has been absolutely obliterated this year, down a stunning 21.2%, which puts the tech-heavy index firmly in bear market territory.

Why the 5 Highest-Yielding Nasdaq Stocks May Be the Best and Safest Value Buys Now

Gilead Sciences, Inc. (NASDAQ: GILD) shares have weakened from $72.27 to $57.19 since the beginning of January 2022, and the current price stands around $59.39. Gilead Sciences reported better than expected first-quarter results last week, and the company's management updated financial guidance for the 2022 fiscal year.

Should I buy Gilead Sciences shares in May 2022?

We think a serious recession is more likely than not, with the signs of crisis and dislocation already showing themselves. In big focus are rates, and the house view is that they'll have to rise more than the market expects to deal with supply shortages.

Top Stocks To Help Prepare For A Recession - We Recommend Gilead Sciences

FOSTER CITY, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance a number of Dragonfly's novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation indications. NK cell engagers represent a novel mechanism with the potential to address a broad range of cancers, including potential for activity in checkpoint resistant and refractory tumors, as well as other di

Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation

BioNTech SE

Eli Lilly

Merck

Check out these pharmaceutical stocks in the stock market today.

Top Pharmaceutical Stocks To Watch In May 2022

RBC Capital Market views Gilead Sciences Inc's (NASDAQ: GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite seasonal headwinds, and in-line operating expenses.  The analyst notes that the story.

Why These Analysts Are Bullish On Gilead's Q1 Earnings

Gilead (GILD) beats on earnings and revenues in the first quarter on strong Veklury sales. HIV business maintains momentum on Biktarvy.

Gilead (GILD) Q1 Earnings Beat on Solid COVID Treatment Sales

Gilead Sciences, Inc. (NASDAQ:GILD ) Q1 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Jacquie Ross - VP, IR Daniel O'Day - Chairman & CEO Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - EVP & CFO Christi Shaw - CEO, Kite Conference Call Participants Michael Yee - Jefferies Brian Abrahams - RBC Capital Markets Geoffrey Meacham - Bank of America Merrill Lynch Robyn Karnauskas - Truist Securities Umer Raffat - Evercore ISI Colin Bristow - UBS Tyler Van Buren - Cowen and Company Gavin Scott - JPMorgan Chase & Co. Guyn Kim - Piper Sandler & Co. Evan Seigerman - BMO Capital Markets Mohit Bansal - Wells Fargo Securities Simon Baker - Redburn Operator Thank you for standing by and welcome to the Gilead Sciences First Quarter 2022 Earnings Conference Call. [Operator Instructions].

News for Gilead Sciences Stock (GILD)